Innoquest

What Innoquest does

Innoquest Pathology Sdn. Bhd. (formerly Gribbles Pathology) is Malaysia's largest private clinical diagnostic laboratory, operating as a subsidiary of Pathology Asia Group. Founded in 1996 and headquartered in Petaling Jaya, the company was formed through the successive mergers of Gribbles Pathology, Quantum Diagnostics (2019), and Clinipath Malaysia (2021), and rebranded under the unified Innoquest name in May 2022. It is the only multidisciplinary clinical laboratory in Malaysia holding both College of American Pathologists (CAP) and MS ISO 15189 accreditations.

The company operates over 85 electronically-linked pathology facilities across Peninsular Malaysia, Sabah, and Sarawak, supported by 1,200+ staff including 20+ in-house pathologists, and processes more than 4 million patient episodes annually. Its technology stack combines digital histopathology with whole-slide imaging, AI-powered imaging algorithms, and a telepathology platform for remote expert consultation, alongside molecular diagnostics platforms such as multiplex PCR (QIAstat-Dx), methylation-specific PCR (COLOTECT), immunoblotting (107-allergen panel), and automated urine culture (Alifax Alfred AST60). Clinician-facing digital tools — the BioMark-powered e-Results portal, e-Ordering system, consumables e-commerce, and chronic disease management modules — anchor the service workflow.

Innoquest generates revenue through B2B diagnostic testing services billed to clinicians, hospitals, and medical centres, with results delivered via e-portal, CRM transmission, or physical courier. Distribution is driven by dedicated Key Account Executives managing relationships with approximately 4,000 GPs and 65 hospitals, supplemented by daily courier specimen pickup, on-site screening services, and Continuing Medical Education programs targeting healthcare professionals. Pricing is not publicly disclosed and is negotiated with registered institutional accounts; the model functions as recurring volume-based testing revenue rather than transactional retail sales.

Name

Innoquest

Legal name

Innoquest Pathology Sdn. Bhd.

Website

https://innoquest.com.my

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Innoquest Pathology is Malaysia's largest private multidisciplinary clinical diagnostic laboratory, serving 4,000+ GPs and 65 hospitals across 85+ facilities with digital histopathology, molecular diagnostics, and routine testing, operating as a subsidiary of Pathology Asia Group.

Ownership category

akta.pro rank

Product category

Clinical Diagnostic Laboratory Services

NAICS

Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB)

akta.pro secondary industries

Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA), Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Clinical diagnostic testing
• Pathology laboratory services
• Digital histopathology
• Molecular diagnostics
• Health screening services

Headquarters

HQ city

Petaling Jaya

HQ country

Malaysia

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Clinical Laboratory Diagnostic Testing Services: Core revenue stream from providing comprehensive diagnostic testing services across haematology, microbiology, biochemistry, molecular pathology, and anatomical pathology. Services delivered to clinicians, hospitals, and medical centres with results delivered via e-portal, CRM transmission, or physical courier.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Innoquest Pathology operates a multi-disciplinary clinical laboratory platform providing diagnostic testing services across anatomical pathology, digital histopathology, haematology, microbiology, biochemistry, molecular diagnostics, allergy screening, infectious disease panels and cancer screening. Services are delivered to clinicians, hospitals and medical centres through 85+ electronically-linked facilities, supported by dedicated courier specimen pickup, phlebotomy, on-site workplace screening and a proprietary BioMark electronic results/ordering platform.

Product overview

Innoquest Pathology is Malaysia's largest private diagnostic laboratory services provider, operating as a unified multidisciplinary clinical laboratory platform. The offering centers on a comprehensive diagnostic testing portfolio spanning anatomical pathology (including digital histopathology with AI-powered imaging), clinical pathology disciplines (haematology, microbiology, biochemistry, molecular diagnostics), and specialized tests including allergy screening (Extensive 107), infectious disease testing (QIAstat-Dx syndromic panels, QuantiFERON-TB, Urea Breath Test), cancer screening (COLOTECT), and urine culture analysis (Alifax Alfred AST60). The platform is augmented by proprietary digital tools including the BioMark-powered e-Results Portal and e-Ordering System, complemented by operational services such as courier pickup, phlebotomy, and on-site screening. The company also provides Continuing Medical Education programs for clinician customers. With over 85 facilities and capacity for 4+ million patient episodes annually, the portfolio functions as an integrated laboratory ecosystem rather than discrete standalone products.

Differentiator

Problem solved

Functional benefit

Brands

• BioMark: Proprietary IT platform for e-results, e-ordering, and electronic records offering document portal and app features including chronic disease management tools.

Products and services

• Laboratory Diagnostic Services Comprehensive multi-disciplinary clinical laboratory testing across haematology, microbiology, biochemistry, molecular diagnostics and anatomical pathology, performing over 4 million patient episodes annually across 85+ facilities for clinicians and hospitals.
• Digital Histopathology Services State-of-the-art digital histopathology service using whole-slide imaging to convert tissue samples into high-resolution digital slides for AI-assisted analysis and remote pathologist review via telepathology.
• QIAstat-Dx Syndromic Testing Multiplex PCR syndromic testing panel providing rapid detection of respiratory (22 targets), gastrointestinal (24 targets) and meningitis/encephalitis (15 targets) infections with results delivered in under 3 hours.
• QuantiFERON-TB Gold Plus (QFT-Plus) Blood test for tuberculosis detection using Interferon Gamma Release Assay (IGRA) technology with CD8+ and CD4+ T cell response measurement, achieving >95% sensitivity and unaffected by BCG vaccination.
• Urea Breath Test (13C-Urea) Gold standard non-invasive in-vivo breath test for Helicobacter pylori detection using 13C-urea measurement of CO2 ratio changes to diagnose peptic ulcer disease and gastritis.
• Extensive 107 Allergens Test In-vitro allergy screening using immunoblotting to measure allergen-specific IgE concentrations across 107 allergens including pollens, dust mites, moulds, foods, venoms and CCD, reported in 91 items from 100µL of serum.
• COLOTECT Faecal DNA Test Non-invasive faecal DNA screening test for early colorectal cancer detection using three methylation biomarkers (SDC2, ADHFE1, PPP2R5C) with multiplex methylation-specific PCR technology achieving 88% sensitivity.
• Alifax Alfred AST60 Urine Culture Analysis Liquid-based urine culture analysis using the Alifax Alfred AST60 analyser with light-scattering technology, 60-sample batch capacity, up to 480 samples per day potential throughput and 8-12 hour turnaround for negative results.
• Courier Specimen Pickup Services Daily courier pickup of specimens from clinics, hospitals and medical centres with online scheduling via sample pickup form; service centred on Klang Valley and expanding nationwide across Malaysia.
• Phlebotomy Services Blood specimen collection services performed by trained phlebotomists to ensure optimal sample quality and quantity for downstream laboratory testing.
• On-Site Health Screening Mobile preventive health screening service delivered at workplaces and communities, providing convenient specimen collection and health assessment programmes.

Quantifiable outcome

• Reduced histopathology turnaround time from one week to 1-2 working days at Sabah facility
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature9 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Jesselton Medical CentrecoreStrategic or Co-development Partner · 14 October 2024Innoquest Pathology partnered with Jesselton Medical Centre in Kota Kinabalu, Sabah, to launch the region's first state-of-the-art digital histopathology laboratory. The facility leverages Innoquest's digital pathology, AI imaging, and telepathology capabilities. The partnership enables processing of over 400 cases monthly with results delivered in 1-2 working days, significantly advancing diagnostic healthcare in East Malaysia.
• AIA MalaysiaminorGTM or Marketing PartnerAIA Malaysia partnered with DOC2US to provide virtual health services and wellness programmes. As a clinical laboratory partner within the broader healthcare ecosystem, Innoquest's diagnostic services support such insurance and wellness initiatives.

Scale indicators7 records

Recent moves8 records

Expansion highlights4 records

Broad incumbents

• Labcorp: Global clinical laboratory and diagnostics company offering comparable test menu breadth across routine and esoteric testing; relevant as a global comparable for Innoquest's scale-up trajectory.
• KPJ Healthcare: Malaysia's largest homegrown private hospital chain with significant captive diagnostic laboratory capacity across its network; competes for the same hospital and physician referral pool as Innoquest.
• Sonic Healthcare: Global clinical laboratory operator with extensive APAC presence; relevant as a comparable business model and potential future regional entrant into Malaysia's diagnostics market.
• Quest Diagnostics: U.S. clinical laboratory leader and the benchmark for scaled multi-disciplinary diagnostic operations; comparable in test menu breadth and B2B clinician focus, and a potential regional expansion competitor.
• Eurofins Scientific: Global testing services group with significant clinical diagnostics and specialty laboratory operations across Asia; comparable in multi-disciplinary, technology-enabled diagnostics delivery.
• Synlab: Europe's largest clinical laboratory services provider with a multi-country hub-and-spoke model closely analogous to Innoquest's 85-facility Malaysian network.

Direct peers

• BP Healthcare: One of Malaysia's largest private diagnostic and health screening chains, operating a multi-disciplinary laboratory and outpatient network directly competing with Innoquest for clinician referrals and patient screening volume.
• Pantai Premier Pathology (IHH Healthcare): Hospital-owned pathology arm of IHH Healthcare's Pantai network, competing directly for the same hospital referral and outpatient diagnostic testing volumes in Malaysia.

Regional players

• Bangkok Dusit Medical Services (BDMS): Thailand's largest private hospital group with significant in-house pathology operations; closely comparable multi-disciplinary clinical laboratory and hospital-integrated diagnostics model in the Southeast Asian region.

Others

• Doctor Anywhere: Regional digital health platform operating in Southeast Asia (including Malaysia) — adjacent ecosystem participant that increasingly integrates with diagnostic lab partners like Innoquest for sample collection and result delivery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/Innoquest.MY
• LinkedInlinkedin.com/company/innoquest-pathology

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innoquest